Data as of .
BBP vs PBE: which is really different?
BBP and PBE hold 34% of their weight in the same names, and BBP returned more over the year.
ETFIQ Off-Index Score: BBP scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
34% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, BBP and PBE hold 34% of their money in the same securities at the same weight.
| Holding | BBP | PBE |
|---|---|---|
| MODERNA INC | 2.50% | 2.75% |
| BIOCRYST PHARMACEUTICALS INC | 1.94% | 2.50% |
| NOVAVAX INC | 1.93% | 3.03% |
| UNITED THERAPEUTICS CORP | 1.85% | 2.70% |
| AMGEN INC | 1.75% | 4.53% |
| EXELIXIS INC | 1.74% | 2.91% |
| BIOGEN INC | 1.74% | 5.07% |
| GILEAD SCIENCES INC | 1.74% | 5.27% |
| TG THERAPEUTICS INC | 1.73% | 2.91% |
| LEGEND BIOTECH CORP | 1.69% | 2.34% |
| HALOZYME THERAPEUTICS INC | 1.64% | 2.91% |
| ARDELYX INC | 1.64% | 2.56% |
| Only in BBP | Only in PBE |
|---|---|
| IMMUNITYBIO INC 4.83% | Natera Inc 5.70% |
| APELLIS PHARMACEUTICALS INC 2.60% | Illumina Inc 5.53% |
| KALVISTA PHARMACEUTICALS INC 2.53% | Royalty Pharma PLC 4.88% |
| IOVANCE BIOTHERAPEUTICS INC 2.45% | QIAGEN NV 2.81% |
| MIRUM PHARMACEUTICALS INC 2.40% | Repligen Corp 2.76% |
| AXSOME THERAPEUTICS INC 2.25% | Protagonist Therapeutics Inc 2.69% |
| KINIKSA PHARMACEUTICALS INTERNATIONAL PL 2.07% | AnaptysBio Inc 2.68% |
| ROIVANT SCIENCES LTD 2.07% | Vericel Corp 2.62% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Sep 19, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| BBP | PBE | BBP | PBE | BBP | PBE | |
| 3 months | +15.3% | +13.2% | +13.1 pts | +11.0 pts | +17.8 pts | +15.7 pts |
| 6 months | +29.5% | +25.9% | +11.5 pts | +7.8 pts | +5.3 pts | +1.6 pts |
| 1 year | +47.5% | +36.2% | +30.9 pts | +19.6 pts | +25.7 pts | +14.4 pts |
| 3 years | +103.0% | +65.0% | +24.6 pts | −13.4 pts | +4.8 pts | −33.1 pts |
| Since launch | +304.4% | +492.4% | −56.6 pts | −311.1 pts | −371.1 pts | −1197.8 pts |
| BBP Virtus Biotech ETF Holds 60 stocks in biotech, 12% of its weight in S&P 500 companies | PBE Invesco Biotechnology & Genome ETF Holds 33 stocks in biotech, 30% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | Virtus | Invesco |
| Theme | Biotech | Biotech |
| In the S&P 500 | 12.4% | 30.0% |
| Active share vs the S&P 500 | 99.0% | 99.0% |
| In the Nasdaq-100 | 8.9% | 19.5% |
| Holdings | 60 | 33 |
| Top ten, share of the fund | 25.7% | 46.7% |
| Expense ratio | 0.34% | 0.59% |
| Fee for the differing part | 0.34% | 0.60% |
| Total return, 1 year | +47.5% | +36.2% |
| vs the S&P 500 | +30.9 pts | +19.6 pts |
| vs the Nasdaq-100 | +25.7 pts | +14.4 pts |
| Below its high | −5.5% | −3.9% |
| Net assets | $59m | $414m |
BBP in plain words
By weight, 12% of BBP's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 26% of the fund across 60 positions, as filed for Apr 30, 2026. Over the year to Sep 18, 2026 the fund returned +47.5% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 30.9 pts. It sits 5.5% below its all-time high of Aug 19, 2026.
PBE in plain words
By weight, 30% of PBE's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 47% of the fund across 33 positions, as published by its issuer for Sep 19, 2026. Over the year to Sep 18, 2026 the fund returned +36.2% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 19.6 pts.
Questions people ask
- Do BBP and PBE hold the same stocks?
- By their latest filings, 34% of their books are the same securities at the same weight, which is a meaningful overlap. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, BBP or PBE?
- BBP has 12% of its weight in S&P 500 names and PBE has 30%, so BBP differs more from the index.
- Which is cheaper, BBP or PBE?
- BBP charges 0.34% a year and PBE charges 0.59%, so BBP is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, BBP against PBE, data as of Sep 18, 2026. https://etfiq.com/compare/themes/bbp-vs-pbe Free to use with attribution; the underlying files are at Open data.